Benchmark Lowers Price Target on Myriad Genetics (MYGN) to $25 After Negative Preannouncement
Tweet Send to a Friend
Benchmark lowers price target on Myriad Genetics (Nasdaq: MYGN) from $30 to $25.
Benchmark analyst says, "We are reducing our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst says, "We are reducing our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
